Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data

ConclusionReal-life data from this post-marketing observational analysis demonstrate the clinical effectiveness and tolerability of 24 weeks of adalimumab biosimilar therapy in Indian patients with RA. This report also reflects upon the treatment strategies and prescription patterns for such therapies in Indian clinical practice.Trial RegistrationISRCTN16838474.FundingCadila Healthcare Limited, India.

http://link.springer.com/10.1007/s40744-019-0166-2

Source: Rheumatology and Therapy - June 27, 2019 Category: Rheumatology Source Type: research